3 – Oxford Longevity Project | Oxford, UK
The Oxford Longevity Project aims to make the latest scientific breakthroughs in longevity accessible to the general public. It is a team of scientists and doctors uniting to change how we understand healthcare for good.
Together, they’ve capitalised on the public’s increased comfort with virtual learning and conferences by holding quarterly global webinars via main online platforms.
What makes OLP unique is their commitment to connect influential clinical practitioners and leading scientists on the same topic.
The speakers have two aims: First and foremost to translate the latest science into accessible information that patients and other interested non-scientists can action themselves; and, second, to more quickly connect doctors to the latest protocols.
Many researchers believe that it takes up to 17 years to translate breakthrough bench research into protocols used in clinics and OLP hope to change this by forging these connections.
One of the scientific discoveries that inhibits ageing are autophagy or cellular renewal, recycling and repair and this led to their previous webcasts ‘Autophagy and Alzheimers’ and ‘Autophagy and Ageing.’ to discuss this topic.
They’re committed to offering free information and empowering people to pursue health and living longer on their own terms, with accessible language, live seminars and free catch-up videos-all at no cost.
- Founders: Leslie Kenny & Oxford University Emeritus Professor Denis Noble
- Explore Oxford Longevity Project
4 – Sano Genetics | UK
This health tech firm matches people to cutting-edge genetic disease research, speeding up the development of personalised medicines.
Using simple at-home DNA saliva testing kits, and via an engaging and secure platform that delivers feedback on contributions and genetic reports, they are transforming the experience of taking part in precision medicine research.
It’s game-changing for researchers who have long struggled to recruit and retain participants.
We still live in an age where it takes 10-15 years and more than $1B to develop a new treatment.
Their tools allow researchers to conduct personalised medicine studies focused on genetic diseases – including rare diseases and genetic subtypes of common disease like Alzheimer’s and Parkinson’s – 10 times faster and at a fifth of the cost.
Its customers are global pharmaceutical and biotech companies, as well as biobanks.
The company was founded in 2017 by three postgraduate students of genomics, and has raised $14.9M in funding to date, including $11M in a recent Series A round.
- Founders: Charlotte Guzzo (COO), Patrick Short (CEO), William Jones (CTO)
- Explore Sano Genetics